Case 01
The exhausted 39-year-old with normal bloods
Case 02
Perimenopausal weight gain despite clean diet
Case 03
Athlete with declining performance and low mood
The exhausted 39-year-old with normal bloods
Three years of symptoms. Multiple NHS consultations. All blood tests within normal range. A pattern hidden across three systems that no single test could reveal.
01 — Intake
Presenting symptoms and history
Sarah is 39, works in project management, has two school-age children. She presents with a three-year history of worsening symptoms that began following a demanding work period and a viral illness. Her GP had told her repeatedly that blood tests were normal and that she was likely stressed or perimenopausal — though her cycle was still regular. Ferritin and Vitamin D had not been tested. Reverse T3 had not been measured. No gut investigation had been performed. No hormonal investigation beyond TSH and FT4.
Deep fatigue — present on waking
Poor sleep — waking 3–4am, 4–5 nights per week
Brain fog — word-finding difficulty, poor concentration
Daily bloating — worse after meals
Weight gain — 8kg over 3 years, primarily abdominal
Anxiety — disproportionate to circumstances
Worsening PMS — past 12 months
Cold hands and feet
Hair thinning — increased shedding
Previous NHS results: TSH 2.4 mIU/L (normal). FT4 14.2 pmol/L (normal). Full blood count normal. AM cortisol 420 nmol/L (normal — single draw). Ferritin not tested. Vitamin D not tested. No gut or hormonal investigation. Dietary history: primarily whole foods, no alcohol, unintentionally low-fat diet due to IBS-type discomfort. 7–8 hours in bed nightly — rarely feeling rested. Exercise: low due to fatigue. Previously ran 5km three times weekly.
02 — Investigation Design
Why these three tests
The presenting pattern — fatigue on waking, 3–4am waking, abdominal weight gain, and worsening PMS with a normal standard thyroid screen — points toward three possible primary drivers not separable from clinical history alone: HPA axis dysfunction, hormonal pattern disruption, and gut-mediated inflammation or nutrient impairment. Each requires specific investigation.
Randox Blood Chemistry
Extended thyroid + iron + metabolic + inflammation
TSH alone is insufficient in a symptomatic individual. FT3, reverse T3, ferritin, hsCRP, fasting insulin, and Vitamin D are all relevant to fatigue and weight gain — none were tested. This establishes the metabolic and nutritional baseline before investigating hormonal and gut layers.
DUTCH Plus
HPA axis diurnal pattern + oestrogen metabolites
The 3–4am waking and disproportionate anxiety point to HPA dysregulation. A single AM cortisol at 420 nmol/L cannot identify whether the diurnal curve is appropriate, whether the CAR is blunted, or whether evening cortisol is elevated. DUTCH also maps oestrogen metabolic pathways — the driver of worsening PMS that serum oestradiol cannot identify.
GI-MAP Stool Analysis
Gut ecology, barrier integrity, oestrogen clearance
Daily bloating with IBS-type symptoms alongside weight gain and suspected poor oestrogen clearance requires gut investigation. Beta-glucuronidase — the enzyme that recirculates conjugated oestrogen back into circulation — is only measurable on GI-MAP. Secretory IgA and calprotectin assess mucosal immune and barrier status.
Deferred: OAT and HTMA
Mitochondrial and mineral layers — held pending Phase 1 findings
OAT (mitochondrial function, organic acid metabolites) and HTMA (mineral excretion pattern, adrenal mineral ratios) would add further layers. Held for Phase 2 if the primary investigation does not fully explain the picture — avoids unnecessary test burden at the outset and ensures protocol sequencing is based on confirmed findings.
03 — Results
Key findings across three investigations
Blood Chemistry — Randox Extended Panel
| Marker | Result | Range | Clinical significance |
|---|---|---|---|
| TSH | 3.8 mIU/L | 0.4–4.0 | High-normal. TSH rises before FT4 falls. Functional threshold in symptomatic individuals is >2.0 mIU/L. |
| Free T3 | 3.1 pmol/L | 3.1–6.8 | At the absolute floor of range. T3 is the metabolically active hormone — this is where the clinical picture sits, not in FT4. Cortisol elevation suppresses T4→T3 conversion. |
| Reverse T3 | 32 ng/dL | <25 | Elevated. Reverse T3 occupies T3 receptors without activating them — acts as a competitive blocker. Chronically elevated cortisol is the primary driver of RT3 production. |
| Ferritin | 16 µg/L | 12–150 | Technically within range — functionally deficient. Ferritin below 30 µg/L is associated with fatigue, hair shedding, and impaired thyroid peroxidase activity. |
| Vitamin D (25-OH) | 28 nmol/L | 50–150 | Deficient. Vitamin D3 is required for T-regulatory cell function, mood regulation, and energy substrate metabolism. |
| Fasting insulin | 11.2 mIU/L | <10 | Mildly elevated. HOMA-IR 2.6 — early insulin resistance. Contributing to abdominal adipose deposition and post-meal energy instability. |
| hsCRP | 2.4 mg/L | <1.0 | Low-grade systemic inflammation. Consistent with gut-derived LPS translocation and metabolic endotoxaemia. |
DUTCH Plus — Hormone and HPA Axis
| Marker | Result | Expected | Clinical significance |
|---|---|---|---|
| Cortisol — waking | 62 (normalised) | 55–100 | Waking cortisol at lower end of expected range. Not low in isolation. |
| CAR — +30 min rise | +18% | +50–100% | Blunted. Only 18% rise vs expected 50–100%. Indicates HPA hypo-reactivity at hypothalamic level — characteristic of Stage 3 HPA exhaustion. The waking cortisol is not low; the axis is not mounting an appropriate morning response. |
| Afternoon cortisol | Low | Normal decline | Lower than expected. Explains energy and concentration crash in early afternoon. |
| Evening cortisol | Elevated | Should fall significantly | Paradoxically elevated. Directly suppresses melatonin onset. Primary driver of the 3–4am waking pattern. |
| Melatonin (6-OHMS) | Low | Age-appropriate | Melatonin suppressed by elevated evening cortisol. The problem is the cortisol pattern — not primary melatonin deficiency. |
| DHEA-S | Low | Normal for age 39 | Depleted. Pregnenolone is the shared precursor for both cortisol and DHEA — chronic cortisol demand diverts pregnenolone away from DHEA production (pregnenolone steal). |
| 2-OHE1:16-OHE1 ratio | 0.9 | >2.0 | Poor. Oestrogen metabolism preferentially toward the 16-OH proliferative pathway. Contributing to PMS, water retention, and oestrogen-driven symptoms despite normal serum oestradiol. |
| 2-MeOE1 | Low | Normal | Insufficient COMT methylation of 2-OH oestrone to the protective 2-MeOE1 form. Indicates methylation insufficiency confirmed by homocysteine elevation on blood panel. |
| Progesterone metabolites | Low-normal | Mid-luteal (day 20) | Collected day 20. Absolute progesterone output borderline adequate — but DHEA depletion and cortisol dominance creating relative oestrogen-to-progesterone imbalance that blood levels alone cannot identify. |
GI-MAP — Stool Analysis
| Marker | Result | Expected | Clinical significance |
|---|---|---|---|
| H. pylori | Positive (low level) | Not detected | Detected at low level. Virulence factors (cagA, vacA) negative — lower-risk strain, but capable of suppressing stomach acid production and contributing to chronic iron depletion through mucosal blood loss. |
| Beta-glucuronidase | 3,800 units | <2,900 | Elevated. This enzyme deconjugates oestrogen-glucuronide in the gut, releasing free oestrogen back into circulation rather than allowing faecal excretion. A direct driver of oestrogen recirculation and worsening PMS — not detectable from any blood test. |
| Secretory IgA | Low | Normal | Mucosal immune defence depleted. Consistent with chronic cortisol suppression of secretory IgA production — a well-documented consequence of sustained HPA activation. |
| Akkermansia muciniphila | Below detection | Detectable | Absent. Akkermansia maintains intestinal mucus layer integrity and barrier function. Absence is associated with increased LPS translocation and metabolic endotoxaemia — explaining the elevated hsCRP on blood chemistry. |
| Calprotectin | 62 µg/g | <50 | Borderline elevated. Low-grade intestinal inflammation consistent with gut barrier dysfunction and LPS-associated immune activation. |
| Elastase-1 | 420 µg/g | >200 | Adequate. Pancreatic enzyme output not compromised — bloating driven by fermentation and dysbiosis, not digestive insufficiency. |
| Candida spp. | Not detected | Not detected | Negative. Candida-oestrogen loop not operative in this case. |
04 — Pattern Recognition
Cross-test pattern identification
Primary pattern — cascade driver
LPS-driven metabolic endotoxaemia → chronic HPA activation → cortisol-mediated thyroid conversion impairment → compounding fatigue
Absent Akkermansia and elevated calprotectin indicate gut barrier dysfunction. LPS from gram-negative bacteria translocates through the compromised barrier, activating systemic inflammatory signalling (hsCRP 2.4 mg/L). This ongoing LPS-driven inflammation maintains cortisol demand — explaining why the HPA axis is chronically activated despite a blunted CAR. The demand here is immunological rather than psychological. Elevated cortisol suppresses TSH and converts T4 preferentially to reverse T3 rather than active T3 — explaining the floor-range FT3 (3.1 pmol/L), elevated RT3 (32 ng/dL), and the thyroid-pattern fatigue and cold extremities. Ferritin depletion (16 µg/L) — partly from H. pylori-associated mucosal blood loss and partly from ongoing inflammation consuming iron stores — compounds both the thyroid problem (ferritin is a cofactor for thyroid peroxidase) and the mitochondrial energy problem.
Cascade sequence
Absent Akkermansia → gut barrier compromise→
LPS translocation→
hsCRP 2.4 (systemic inflammation)→
Chronic cortisol demand→
Blunted CAR + elevated evening cortisol→
Elevated RT3, floor-range FT3→
DHEA depletion + melatonin suppression→
Fatigue, weight gain, non-restorative sleep
Secondary pattern — oestrogen recirculation
Elevated beta-glucuronidase → oestrogen recirculation → impaired COMT methylation → poor 2:16 ratio → worsening PMS
Beta-glucuronidase at 3,800 deconjugates oestrogen-glucuronide in the gut, returning free oestrogen to circulation rather than allowing excretion. This is not visible from DUTCH oestrogen production values (normal) or from serum oestradiol — it is only measurable on GI-MAP. Combined with impaired COMT methylation (low 2-MeOE1 on DUTCH), the 2-OH pathway oestrogen that is produced is not converted efficiently to the protective 2-MeOE1 form. The 2:16 ratio of 0.9 (target >2.0) reflects both impairments simultaneously: oestrogen recirculating from the gut, and inadequate protective methylation of what is produced. This explains worsening PMS and water retention in the context of normal serum oestradiol.
Oestrogen cascade
High beta-glucuronidase (GI-MAP 3,800)→
Oestrogen recirculation from gut→
Impaired COMT methylation (low 2-MeOE1)→
2:16 ratio 0.9 (target >2.0)→
Worsening PMS + water retention
05 — Protocol
Three-phase protocol — sequenced from root causes
Protocol is sequenced from root causes to downstream effects. The gut drives the cortisol pattern; the cortisol pattern drives the thyroid conversion problem. Beginning with methylation support or thyroid support before addressing gut and cortisol drivers would produce partial and temporary benefit. Phase 1 addresses the root; Phases 2 and 3 build on the restored foundation.
Phase 1 · Weeks 1–6
Gut, barrier, H. pylori
H. pylori: mastic gum 1g twice daily + berberine 500mg + DGL — 8 week protocol. Non-virulent strain; pharmacological eradication discussed, deferred by client preference initially
Akkermansia restoration: pomegranate extract (ellagic acid 400mg) + inulin 5g prebiotic + Akkermansia-containing probiotic blend
Gut barrier: L-glutamine 5g AM, zinc carnosine 75mg, collagen peptides 10g
Beta-glucuronidase reduction: calcium D-glucarate 500mg twice daily with meals
Temporary gluten removal given low sIgA and borderline calprotectin — reducing immune activation burden
Phase 2 · Weeks 4–12
HPA support, nutrients, methylation
HPA axis: ashwagandha KSM-66 600mg AM (CAR-normalising evidence in clinical trials), Rhodiola rosea 400mg AM
Evening cortisol lowering: phosphatidylserine 300mg at 4pm (documented cortisol-lowering at therapeutic dose); magnesium glycinate 400mg at bedtime
Methylation: methylcobalamin 1mg + methylfolate 400mcg + riboflavin 50mg — COMT cofactors for oestrogen clearance via 2-MeOE1 pathway
Iron repletion: ferrous bisglycinate 28mg with Vitamin C — gradual titration to avoid tolerance issues
Vitamin D3 + K2: 4,000 IU D3 daily — retest at 12 weeks
Phase 3 · Weeks 8–24
Oestrogen metabolism + metabolic
DIM 200mg introduced at week 8 — after gut barrier restoration. DIM absorption requires adequate mucosal integrity; introducing earlier would have been suboptimal and potentially destabilising
Insulin sensitivity: berberine 500mg twice daily (already in H. pylori protocol — continued for metabolic effect); reduce refined carbohydrate load
Movement reintroduction: work-in programme first — Qi gong and walking weeks 4–8; aerobic training reintroduced week 8 once energy sustainably improving
Sleep: evening light management, screen curfew; melatonin 0.5mg discussed if waking persists after evening cortisol normalises at retest
06 — Outcome
Progress at 12 weeks and 6 months
12-week assessment
Subjective report + retest bloods
Fatigue: significantly improved — energy sustainable through the working day without requiring afternoon rest
Sleep: 3–4am waking reduced from 4–5 nights per week to 1–2. Sleep quality improving noticeably
Bloating: substantially resolved. Digestive symptoms largely cleared by week 6
Ferritin retest: 38 µg/L (from 16 µg/L). Hair shedding reduced noticeably from week 8
Vitamin D: 74 nmol/L (from 28 nmol/L). Within optimal range
hsCRP: 0.9 mg/L (from 2.4 mg/L) — below threshold
Fasting insulin: 7.8 mIU/L (from 11.2). HOMA-IR 1.7
Weight: 4kg reduction, predominantly abdominal
6-month full retest
DUTCH + GI-MAP re-assessment
Energy: running 5km twice weekly — sustained throughout the day consistently
Sleep: restorative. Waking reduced to occasional — coinciding with high-stress periods only
FT3: 4.8 pmol/L (from 3.1). Mid-range. Reverse T3: 18 ng/dL (from 32 ng/dL)
PMS: significantly improved. Months 2–3 showed temporary worsening — predicted at outset as beta-glucuronidase fell and oestrogen load pattern changed before clearance mechanisms were established. Progressive improvement thereafter
DUTCH retest: CAR improved to 58% rise (from 18%). Evening cortisol normalised. 2:16 ratio improved to 1.8 (from 0.9)
GI-MAP retest: H. pylori not detected. Beta-glucuronidase 1,840 (from 3,800). Akkermansia detectable. Secretory IgA improved to normal range
Total weight change: 7kg over 6 months — predominantly visceral adipose reduction
07 — Clinical Learning
What this case demonstrates about integrated pattern recognition
Key principles illustrated
Why cross-test pattern recognition is different from treating each result in isolation
A blunted CAR with elevated evening cortisol does not automatically identify the cause of the cortisol pattern. Here, gut-derived LPS was the primary driver of cortisol demand. Treating the HPA axis without addressing the gut would have produced incomplete and temporary benefit — the demand would remain.
Reverse T3 elevation explained the thyroid-pattern fatigue that TSH and FT4 could not. RT3 is not in standard NHS thyroid testing. The floor-range FT3 (3.1 pmol/L) was technically normal — the RT3 made the clinical significance of that value interpretable. Without it, this case looks like "normal thyroid."
Beta-glucuronidase on GI-MAP was the missing piece in the oestrogen picture. DUTCH showed impaired oestrogen metabolism; serum oestradiol was normal. Neither alone identified the gut-oestrogen recirculation loop — only the combination of GI-MAP beta-glucuronidase and DUTCH metabolic pathway data revealed the mechanism.
The worsening PMS in months 2–3 was a sign of treatment progress, not failure. As beta-glucuronidase fell, the pattern of oestrogen loading changed before the clearance mechanisms were fully operational — a predictable transition that required clear communication to Sarah at the start of the protocol.
DIM introduction was deliberately deferred until week 8. Gut barrier restoration is a prerequisite for effective DIM absorption and downstream oestrogen pathway benefit. Introducing it in week 1 with a compromised mucosal barrier would have been clinically appropriate in principle but less effective in practice — and potentially disruptive to the oestrogen balance during early-phase gut healing.
Perimenopausal weight gain despite a clean diet
Weight accumulating around the hips and abdomen over 18 months. Diet unchanged — arguably cleaner than it had ever been. Hormone tests showed oestrogen "within range." The mechanism driving the weight gain was in the gut, not the ovaries.
01 — Intake
Presenting symptoms and history
Karen is 48, a secondary school teacher, perimenopausal with cycles becoming irregular over the past year. Her presenting complaints are weight gain — particularly around the hips, abdomen, and lower back — breast tenderness in the week before her period, worsening mood and anxiety in the luteal phase, and a persistent low-level fatigue that is different from tiredness. Sleep is disrupted but not absent. Her GP has checked oestrogen and FSH, found them "consistent with perimenopause," and offered HRT. Karen wants to understand what is driving the symptoms before deciding on HRT.
Dietary history: largely whole food, low processed food, no alcohol. She has noticed that the weight gain has continued despite reducing carbohydrates. She takes a standard multivitamin. She has had two courses of antibiotics in the past three years for recurrent UTIs.
02 — Investigation Design
Why these three tests
The symptom cluster — luteal phase mood symptoms, breast tenderness, weight distribution around hips and abdomen — is consistent with oestrogen dominance. But "oestrogen dominance" is a pattern that can arise from several different mechanisms: excess oestrogen production, impaired oestrogen clearance through liver Phase II pathways, oestrogen reactivation in the gut via dysbiotic bacteria, or progesterone insufficiency relative to oestrogen. A serum oestrogen measurement tells you the blood level at a point in time. It does not tell you how oestrogen is being metabolised, which pathways are active or impaired, or what is happening to oestrogen after the liver has processed it.
DUTCH Plus
Full oestrogen metabolite mapping and HPA axis
The DUTCH measures oestrogen metabolites — 2-OH, 4-OH, and 16-OH oestrone — which reveal which detoxification pathway is dominant. It also measures Phase II conjugation markers (glucuronidation and sulphation) and provides a full cortisol rhythm. Critically, it shows whether oestrogen is being converted via the protective 2-OH pathway or the proliferative 16-OH pathway, which serum oestrogen cannot reveal.
GI-MAP
Beta-glucuronidase and gut microbiome
Beta-glucuronidase is an enzyme produced by dysbiotic bacteria that deconjugates oestrogens the liver has already packaged for excretion — allowing them to be reabsorbed into circulation. Two courses of antibiotics represent a significant microbiome disruption event. GI-MAP will show dysbiosis patterns, pathogenic organisms if present, immune markers, and beta-glucuronidase directly.
Blood Chemistry — Randox
Metabolic and liver function context
Liver function markers (GGT, ALT, AST) at functional optimal ranges will show whether the liver's detoxification capacity is under strain. Thyroid conversion (free T3, reverse T3) is relevant given the fatigue and metabolic slowdown. Fasting insulin and HbA1c will clarify whether blood sugar dysregulation is contributing to the weight pattern.
03 — Results
Key findings across three investigations
DUTCH Plus — Hormone and Oestrogen Metabolites
| Marker | Result | Functional Range | Clinical Note |
|---|---|---|---|
| Morning cortisol | Adequate | Normal | HPA axis intact — stress not the primary driver here |
| DHEA-S | Low-normal | Mid-range optimal | Adrenal reserve reduced — typical perimenopausal pattern |
| Progesterone metabolites | Low | Should balance oestrogen | Luteal phase progesterone insufficient — consistent with perimenopausal transition |
| 2-OH oestrone (protective) | Low | Should be dominant pathway | Protective 2-OH pathway underactive |
| 16-OH oestrone (proliferative) | Elevated | Should be minor pathway | Proliferative pathway dominant — drives weight, breast tenderness, mood symptoms |
| 2-OH:16-OH ratio | 0.8 (low) | >2.0 optimal | Significantly skewed toward proliferative pathway |
| Phase II glucuronidation | Impaired | Should be active | Liver's oestrogen conjugation for excretion compromised |
GI-MAP — Stool Analysis
| Marker | Result | Clinical Note |
|---|---|---|
| Beta-glucuronidase | Elevated (3.2 x upper limit) | Key finding — oestrogen deconjugation enzyme elevated. Reabsorption of excreted oestrogens likely. |
| Secretory IgA (sIgA) | Low | Gut immune defence depleted — consistent with antibiotic history |
| Beneficial Lactobacillus | Depleted | Post-antibiotic dysbiosis pattern |
| Prevotella species | Elevated | High beta-glucuronidase producers — directly contributing to oestrogen recirculation |
| Candida | Borderline | Opportunistic, not dominant — monitor alongside gut repair |
| Zonulin | Elevated | Intestinal permeability increased — gut barrier compromise |
Blood Chemistry — Randox Extended Panel
| Marker | Result | Functional Range | Clinical Note |
|---|---|---|---|
| GGT | 38 U/L | <20 optimal | Liver detoxification under strain — consistent with DUTCH Phase II impairment |
| ALT | 28 U/L | <20 optimal | High-normal — liver burden confirmed |
| Free T3 | 3.8 pmol/L | 5.0–7.0 optimal | Thyroid conversion impaired — contributing to metabolic slowdown and fatigue |
| Ferritin | 26 µg/L | 50–100 optimal | Sub-optimal — T4 to T3 conversion further compromised |
| Fasting insulin | 8.2 µIU/mL | <5 optimal | Elevated — insulin resistance early pattern, contributing to weight distribution |
04 — Pattern Recognition
Cross-test pattern identification
Primary pattern — oestrogen recirculation loop
The mechanism is a closed loop operating across gut, liver, and systemic circulation. Antibiotic use disrupted the microbiome, reducing beneficial bacteria and allowing Prevotella and other high-beta-glucuronidase producers to proliferate. These bacteria are producing beta-glucuronidase in quantities 3.2 times the upper limit — actively deconjugating oestrogens the liver has packaged for excretion and releasing them back into circulation.
The liver, already under metabolic strain (GGT, ALT elevated at functional ranges), has impaired Phase II conjugation — glucuronidation is compromised, meaning less oestrogen is being packaged for excretion in the first place. The DUTCH confirms the metabolite consequence: the 2-OH:16-OH ratio is 0.8 against an optimal of 2.0 or above, with the proliferative 16-OH pathway dominant.
The weight gain, breast tenderness, and luteal mood symptoms are not primary menopausal oestrogen excess. They are the downstream consequence of oestrogen that was processed correctly, excreted correctly, and then reabsorbed from the gut because of dysbiosis-produced beta-glucuronidase. The source is bacterial. The mechanism is hepatic. The symptom is hormonal.
Secondary pattern — metabolic slowdown compounding weight
Ferritin at 26 µg/L is below the functional threshold for optimal deiodinase activity. The free T3 of 3.8 pmol/L — low despite an adequate TSH — is consistent with iron-limited T4 to T3 conversion. The metabolic slowdown this produces is contributing to the weight pattern independently of the oestrogen recirculation. Early insulin resistance (fasting insulin 8.2 µIU/mL) is directing calories preferentially into fat storage, particularly around the abdomen and hips — the anatomical pattern consistent with insulin-driven fat deposition.
05 — Protocol
Three-phase protocol — addressing root causes in sequence
Phase 1 · Weeks 1–8
Gut microbiome restoration and beta-glucuronidase reduction
Reduce beta-glucuronidase-producing bacteria through targeted botanical antimicrobials (berberine, oregano oil). Restore Lactobacillus populations with high-potency Lactobacillus-dominant probiotics — Lactobacillus acidophilus and rhamnosus are confirmed low-beta-glucuronidase producers. Gut barrier repair: L-glutamine, zinc carnosine, quercetin. Dietary: reduce dietary glucuronides temporarily (cruciferous vegetables paradoxically increase beta-glucuronidase in dysbiotic gut — reintroduce once microbiome stabilises).
Phase 2 · Weeks 6–16
Liver Phase II support and oestrogen detoxification
Support glucuronidation pathway: calcium-d-glucarate (inhibits beta-glucuronidase and supports conjugation simultaneously). DIM (diindolylmethane) to shift oestrogen metabolism toward 2-OH pathway. Methylation support: methylated B vitamins (folate, B12, B6) to support Phase II sulphation. N-acetyl cysteine for glutathione and liver support. Reintroduce cruciferous vegetables as gut stabilises.
Phase 3 · Weeks 8–20
Metabolic restoration — iron, thyroid conversion, insulin sensitivity
Restore ferritin to 50–100 µg/L range through dietary iron optimisation (red meat, liver) and supplemental iron bisglycinate if dietary approach insufficient. Monitor free T3 response as ferritin rises — expect improvement in thyroid conversion. Blood sugar: time-restricted eating window, reduce refined carbohydrates, increase fibre. Magnesium glycinate for insulin sensitisation. Review at 16 weeks with repeat DUTCH and GI-MAP markers.
06 — Outcome
Five-month review
At the five-month review, Karen reported that breast tenderness had resolved by week six. Luteal phase mood symptoms had significantly improved by week ten. Weight had reduced by 4.2 kg over the full period, with the abdominal distribution visibly changed. Sleep was consistently better from week eight. Fatigue had improved substantially, which she attributed primarily to improved sleep quality but which is also consistent with improved thyroid conversion as ferritin rose.
Follow-up GI-MAP at month four showed beta-glucuronidase within normal range. Prevotella significantly reduced. Lactobacillus populations restored. Zonulin within normal range. DUTCH repeat showed 2-OH:16-OH ratio improved to 1.8 — not yet at optimal but substantially corrected. Phase II glucuronidation improved. Ferritin at follow-up blood chemistry: 58 µg/L. Free T3: 4.9 pmol/L. Fasting insulin: 5.8 µIU/mL.
HRT was not initiated. Karen's decision, made after reviewing the mechanism and the progress. The symptoms that had prompted the HRT conversation resolved through addressing the microbiome and liver detoxification pathway. The perimenopausal transition continues — the hormonal shift is real — but the oestrogen dominance symptoms were driven by a mechanism that had nothing to do with menopause and everything to do with two courses of antibiotics and the gut ecosystem disruption they produced.
The athlete with declining performance and low mood
Competitive amateur cyclist. Training load unchanged. Performance declining for six months. Testosterone "fine" according to his GP. Mood increasingly flat. The data told a different story — one about what happens when the body cannot sustain the energy demands being placed on it.
01 — Intake
Presenting symptoms and history
James is 34, a software engineer, competitive amateur cyclist with a structured training programme of 10–14 hours per week. His performance has been declining for six months — power output down, recovery slower, motivation to train diminishing. His mood has become flat in a way he describes as "not depressed, just not engaged." Sleep is adequate in duration but not restorative. He has been told by his GP that his testosterone is "normal" — total testosterone 13.2 nmol/L — and that he may simply be overtraining.
Training history: he increased training volume by approximately 25% ten months ago in preparation for a sportive. Performance improved initially, then began declining around four months later. He has not reduced training load, believing the decline reflects a fitness deficit he needs to train through.
Diet: high carbohydrate, moderate protein. Uses whey protein post-training. Caloric intake appears adequate on self-report. Takes magnesium and a B-complex. No significant gut symptoms. Sleep: 7–8 hours, wakes occasionally, does not feel rested.
02 — Investigation Design
Why these three tests
The picture of declining athletic performance with low mood, non-restorative sleep, and a testosterone result at the lower end of "normal" in the context of significantly increased training load points toward a specific hypothesis: the HPA axis is under sufficient chronic stress from training load that it is competing with the HPG (hypothalamic-pituitary-gonadal) axis for precursor resources — specifically pregnenolone — and the mitochondrial energy systems required to sustain both training output and hormonal production are compromised. This is sometimes called overtraining syndrome, but that label describes the symptom pattern rather than the mechanism.
OAT — Organic Acids Test
Mitochondrial function and energy production
The OAT is the primary investigation here because declining performance with adequate training should be explained by energy production failure first. Krebs cycle markers, mitochondrial function, CoQ10 status, B-vitamin cofactor availability, and mitochondrial oxidative stress markers will reveal whether the cells are producing ATP efficiently.
DUTCH Plus
Cortisol rhythm and testosterone context
DUTCH will show the full cortisol diurnal pattern — whether the adrenals are in a high-demand stress response, beginning to exhaust, or already suppressed. DHEA-S relative to cortisol shows the anabolic-catabolic balance. Free testosterone cannot be assessed from a single serum measurement without SHBG — DUTCH provides the urinary androgens picture including DHEA-S, testosterone, and metabolites.
Blood Chemistry — Randox
Iron, thyroid, metabolic and cardiovascular context
Ferritin and iron studies: endurance training creates significant iron demand — foot strike haemolysis, GI blood loss, sweat losses, and increased erythropoiesis all deplete iron. Ferritin below 50 µg/L in an endurance athlete is a functional performance impairment regardless of haemoglobin. Free T3 will show whether thyroid conversion is supporting the metabolic demand. SHBG will contextualise the GP's testosterone result.
03 — Results
Key findings across three investigations
OAT — Organic Acids and Mitochondrial Markers
| Marker | Result | Clinical Note |
|---|---|---|
| Citric acid (Krebs cycle) | Significantly elevated | Krebs cycle bottleneck — mitochondria attempting to run cycle faster than cofactors allow |
| Succinic acid | Elevated | Accumulation upstream of bottleneck — confirms mitochondrial inefficiency |
| Malic acid | Elevated | Further Krebs intermediate accumulation |
| 3-hydroxy-3-methylglutaric (HMG) | Elevated | CoQ10 depletion marker — HMG-CoA reductase pathway active, CoQ10 synthesis impaired |
| Pyridoxic acid (B6 marker) | Low | B6 insufficiency — cofactor for multiple mitochondrial enzymes and testosterone synthesis |
| Pantothenic acid (B5) | Low-normal | Required for CoA synthesis — energy metabolism cofactor |
| 8-OHdG (oxidative stress) | Elevated | Mitochondrial oxidative stress — cellular damage from energy production inefficiency |
DUTCH Plus — Cortisol, DHEA and Androgens
| Marker | Result | Functional Range | Clinical Note |
|---|---|---|---|
| Morning cortisol | High-normal | Should peak then decline | HPA axis in sustained activation |
| Evening cortisol | Elevated | Should be minimal | Evening cortisol elevation — cortisol not clearing, impairing sleep architecture and overnight testosterone production |
| DHEA-S | Low | Should be 2:1 vs cortisol or higher | Cortisol:DHEA-S ratio heavily skewed catabolic — the body is breaking down faster than it is rebuilding |
| Testosterone (urinary) | Low-normal | Mid-range optimal for age | Consistent with pregnenolone being diverted to cortisol production |
| Melatonin | Low | Should peak overnight | Sleep architecture compromise — overnight testosterone synthesis window reduced |
| Androsterone:Etiocholanolone | Skewed | Should be balanced | Androgen metabolism pattern consistent with high cortisol diversion |
Blood Chemistry — Randox Extended Panel
| Marker | Result | Functional Range | Clinical Note |
|---|---|---|---|
| Ferritin | 22 µg/L | 50–100 optimal (athletes: 70+) | Significantly sub-optimal for endurance athlete — iron demand from training not being met |
| Serum iron | Low-normal | Mid-range optimal | Consistent with depleted ferritin stores |
| Transferrin saturation | 18% | 25–35% optimal | Iron delivery to tissues impaired |
| Free T3 | 3.6 pmol/L | 5.0–7.0 optimal | Thyroid conversion impaired — iron-limited deiodinase. Metabolic rate suppressed despite high training load. |
| SHBG | 52 nmol/L | 20–30 optimal | Elevated SHBG binding testosterone — free testosterone fraction reduced significantly below what total testosterone suggests |
| Total testosterone | 13.2 nmol/L | GP "normal" | With SHBG at 52, calculated free testosterone is below the functional optimal for a 34-year-old male athlete |
| CRP | 2.8 mg/L | <1.0 optimal | Chronic low-grade inflammation — consistent with oxidative stress from training and mitochondrial inefficiency |
04 — Pattern Recognition
Cross-test pattern identification
Primary pattern — mitochondrial insufficiency under training demand
The OAT tells the primary story. James is demanding energy output from a mitochondrial system that cannot sustain it efficiently. The Krebs cycle markers show accumulation of intermediates at multiple points — the cycle is running but the cofactors required to process them (CoQ10, B vitamins, iron for electron transport chain) are depleted. The HMG marker is particularly significant: it indicates that the mevalonate pathway — normally used in part for CoQ10 synthesis — is being diverted, further impairing the mitochondrial efficiency that is already failing.
He is training on a depleted energy production system and working harder to produce the same output. This is the physiological explanation for declining performance at unchanged training load.
Secondary pattern — HPA-HPG axis competition
The DUTCH shows a classic overreaching pattern: sustained cortisol elevation (particularly the evening elevation), DHEA-S suppressed, and the cortisol:DHEA-S ratio so skewed catabolic that the body is literally breaking down more than it is rebuilding. The elevated evening cortisol is preventing the nocturnal testosterone production window — testosterone is synthesised primarily in deep sleep, which requires cortisol to be low and melatonin adequate. Neither condition is being met.
The GP's testosterone result of 13.2 nmol/L passed clinical review because SHBG was not measured. With SHBG at 52 nmol/L, the free testosterone fraction is substantially below what a 34-year-old male athlete needs to support training recovery. The "normal" testosterone result was, in context, a low testosterone story.
Tertiary finding — iron depletion driving compounding failures
Ferritin at 22 µg/L in a high-volume endurance athlete is a significant finding. Iron is a cofactor in the electron transport chain (mitochondrial energy production), in deiodinase enzymes (thyroid conversion), and in haemoglobin synthesis. The free T3 at 3.6 pmol/L indicates impaired thyroid conversion — metabolic rate is suppressed at exactly the point where training demands it to be elevated. The combination of mitochondrial inefficiency, suppressed thyroid conversion, and elevated SHBG creating low free testosterone is producing a compounding performance impairment across three systems simultaneously.
05 — Protocol
Four-phase protocol — energy systems first, hormones follow
Phase 1 · Weeks 1–4
Training load reduction and recovery priority
Non-negotiable: training volume reduced by 30–40% for four weeks. This is not optional — supplementing a depleted mitochondrial system while continuing to deplete it further will not produce recovery. The reduction is framed as a deliberate periodisation block, not a failure. Sleep prioritised: consistent sleep window, room temperature optimisation, no screens after 10pm, magnesium glycinate 400mg before bed to support melatonin and cortisol clearance.
Phase 2 · Weeks 2–12
Mitochondrial cofactor restoration
CoQ10 as ubiquinol (active form, higher bioavailability) 200–400mg daily with food. Methylated B-complex to address B6 and B5 deficiencies identified on OAT. Alpha-lipoic acid as mitochondrial antioxidant and recycling agent. Iron bisglycinate — targeted dose to restore ferritin toward 70+ µg/L, monitored monthly to avoid overshoot. Dietary: increase haem iron sources (red meat, liver), optimise vitamin C with iron-containing meals for absorption.
Phase 3 · Weeks 4–16
HPA recovery and testosterone support
Adaptogenic support for HPA recovery: ashwagandha (KSM-66, 600mg, morning) — evidence base for cortisol reduction and DHEA-S support, directly relevant to the cortisol:DHEA-S ratio. Phosphatidylserine 300mg in afternoon — blunts evening cortisol elevation, supports the nocturnal testosterone window. Zinc and vitamin D: both required for testosterone synthesis and were below functional optimal on blood chemistry.
Phase 4 · Weeks 8–16
Graduated training return with performance monitoring
Training volume restoration over 8 weeks, monitoring power output and recovery quality as objective markers. Subjective mood and motivation tracked as secondary markers of HPA recovery. Performance metrics used as real-world validation of protocol response. Target: return to previous training volume at improved performance by week 16. If not achieved, repeat OAT to confirm mitochondrial marker normalisation before further volume increase.
06 — Outcome
Four-month review
James reduced training volume as instructed, which he described as "harder psychologically than I expected." By week six, sleep quality had improved markedly — he was waking less frequently and describing sleep as restorative for the first time in months. Mood began to lift from week five, which he attributed to the improved sleep before any supplement effect would be expected.
By week ten, at 60% of his previous training volume, his power output at threshold effort had returned to the level he was producing at full training volume before the decline began. This was an unexpected data point for him — he had assumed more training was always more output.
At the four-month review: ferritin 68 µg/L. Free T3 4.8 pmol/L. SHBG had dropped to 38 nmol/L as cortisol normalised — free testosterone improved significantly within the unchanged total testosterone result. CRP 0.8 mg/L. DUTCH repeat showed morning cortisol appropriate, evening cortisol normalised, DHEA-S improved substantially, melatonin restored.
He did not receive testosterone therapy. He received four weeks of reduced training, mitochondrial cofactor support, iron restoration, and sleep prioritisation. The testosterone was low because the system supporting it was under sustained stress. Address the system, the testosterone follows. The GP's "normal" result was correct as a number. It was incomplete as a clinical story.